Company Overview and News

0
ECA2018-94 - Information Regarding the Reclassification of the Variable Voting Shares of DHX Media Ltd. (DHXM)

2018-05-30 nasdaqtrader
Beginning on Thursday, May 31, 2018, the Variable Voting Shares of DHX Media Ltd. (DHXM) will be reclassified to represent both a variable voting share and common voting share. The CUSIP number will be updated to 252406152. The details are as follows:
DHX.A DHXM DMQHF

91
Forge First Funds April 2018 Commentary - Danger With Canadian Natural Gas

2018-05-20 seekingalpha
April experienced more of the same volatility in equity markets that has persisted for most of the year, and as a result, Forge First continued to play things safe, ending another month with positive net returns for investors. Expectations around inflation caused the US 10-Year Treasury yield to briefly touch 3% for the first time in over four years, oil prices increased 7% for the month (making commodities the top performing asset class), and of the 32% of S&P 500 companies having reported more than 75% exceeded expectations.
PXT DHXM PARXF CAT CF WCP GOOG CIFAF ENB CF.PR.C CCORF EQB TNEYF CF.PR.A TOLWF DHX.A TOU ENB V JPM GOOGL EQGPF CIX DMQHF TRMLF SPGYF CF

26
Sony's Subsidiary to Acquire a Stake in Peanuts Holdings

2018-05-15 zacks
Sony Corporation’s (SNE - Free Report) wholly-owned subsidiary, Sony Music Entertainment, recently entered into a definitive agreement with DHX Media Ltd. Per the deal, Sony Music will acquire 49% of the 80% equity interest held by DHX Media in Peanuts Holdings LLC. Notably, this $185-million agreement is expected to conclude on or about Jun 30, 2018.
DHX.A CABO PVH DHXM ZEEEY 505537 DMQHF SNE TSG SNEJF ZEEL

0
DHX Media - Turning Positive

2018-05-15 seekingalpha
The deal to sell 39% of Peanuts to Sony could make a big difference towards reducing the heavy debt burden.
DHX.A DHXM DMQHF

8
DHX Media to cut debt load with money from Sony-Peanuts deal, CEO says

2018-05-14 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
DHX.A DHXM DMQHF SNE SNEJF

8
DHX Media to cut its debt with money from Peanuts deal with Sony: CEO

2018-05-14 cbc.ca
DHX Media Ltd. said Monday the sale of nearly half of its stake in the Peanuts entertainment business to a Sony Corp. division for $237 million in cash will help reduce the Canadian animation company's debt load and improve its operating results.
DHX.A DHXM DMQHF SNE SNEJF

6
PRESS DIGEST-Canada-May 14

2018-05-14 reuters
May 14 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
DHX.A DHXM KMI.PRA KMI KMI.WS DMQHF KMR KMRFZ CVB

8
Sony Music unit buying stake in Canadian company that partially owns Peanuts

2018-05-14 japantimes.co.jp
Electronics giant Sony Corp.’s music unit said Monday that it is buying a stake in Peanuts Holdings, the company behind Snoopy and Charlie Brown.
DHX.A DHXM DMQHF SNE SNEJF

8
Snoopy joining Sony? Music unit buying stake in Peanuts

2018-05-14 business.inquirer.net
Snoopy, right, throws out the ceremonial first pitch while Charlie Brown looks on prior to the New York Mets playing the Houston Astros in a baseball game at Citi Field in New York in this 2009 file photo. (AP)
DHX.A DHXM DMQHF SNE SNEJF

8
Snoopy joining Sony? Music unit buying stake in Peanuts

2018-05-14 nzherald.co.nz
TOKYO (AP) — Japanese electronics maker Sony Corp.'s music unit is buying a stake in Peanuts Holdings, the company behind Snoopy and Charlie Brown.
DHX.A DHXM DMQHF SNE SNEJF

0
BRIEF-DHX Media Ltd Says Aaron Ames Appointed Chief Operating Officer

2018-04-18 reuters
* DHX MEDIA - CO-FOUNDER STEVEN DENUREE TRANSITIONING OUT OF ROLE AS PRESIDENT AND COO WITHIN NEXT MONTH Source text for Eikon: Further company coverage:
DHX.A DHXM DMQHF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...